Meredith A Ray1, Carrie Fehnel2, Olawale Akinbobola2, Nicholas R Faris3, Meghan Taylor2, Alicia Pacheco2, Matthew P Smeltzer1, Raymond U Osarogiagbon4. 1. Division of Epidemiology, Biostatistics, and Environmental Health, School of Public Health, University of Memphis, Memphis, Tennessee. 2. Thoracic Oncology Research Group, Baptist Cancer Center, Memphis, Tennessee. 3. Thoracic Oncology Research Group, Baptist Cancer Center, Memphis, Tennessee; Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, Tennessee. 4. Thoracic Oncology Research Group, Baptist Cancer Center, Memphis, Tennessee; Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, Tennessee. Electronic address: rosarogi@bmhcc.org.
Abstract
INTRODUCTION: The adverse prognostic impact of poor pathologic nodal staging has stimulated efforts to heighten awareness of the problem through guidelines, without guidance on processes to overcome it. We compared heightened awareness (HA) of nodal staging quality versus a lymph node collection kit. METHODS: We categorized curative-intent lung cancer resections from 2009 to 2020 in a population-based, nonrandomized stepped-wedge implementation study of both interventions, into preintervention baseline, HA, and kit subcohorts. We used differences in proportion and hazard ratios across the subcohorts to estimate the effect of the interventions on poor quality (nonexamination of nodes [pNX] or nonexamination of mediastinal lymph nodes) and attainment of quality recommendations of the National Comprehensive Cancer Network, the Commission on Cancer, and the proposed complete resection definition of the International Association for the Study of Lung Cancer across the three cohorts. RESULTS: Of 3734 resections, 39% were preintervention, 40% kit, and 21% HA cases. Cohort proportions were the following: pNX, 11% (baseline) versus 0% (kit) versus 9% (HA); nonexamination of mediastinal lymph nodes, 27% versus 1% versus 22%; Commission on Cancer benchmark attainment, 14% versus 77% versus 30%; International Association for the Study of Lung Cancer-defined complete resection, 11% versus 58% versus 24%; National Comprehensive Cancer Network attainment, 23% versus 79% versus 35% (p < 0.001 for all, except pNX rate baseline versus HA). Survival rate was significantly higher for both interventions compared with baseline (p < 0.0001). CONCLUSIONS: Resections with HA or the kit significantly improved surgical quality and outcomes, but the kit was more effective. We propose to conduct a prospective, institutional cluster-randomized clinical trial comparing both interventions.
INTRODUCTION: The adverse prognostic impact of poor pathologic nodal staging has stimulated efforts to heighten awareness of the problem through guidelines, without guidance on processes to overcome it. We compared heightened awareness (HA) of nodal staging quality versus a lymph node collection kit. METHODS: We categorized curative-intent lung cancer resections from 2009 to 2020 in a population-based, nonrandomized stepped-wedge implementation study of both interventions, into preintervention baseline, HA, and kit subcohorts. We used differences in proportion and hazard ratios across the subcohorts to estimate the effect of the interventions on poor quality (nonexamination of nodes [pNX] or nonexamination of mediastinal lymph nodes) and attainment of quality recommendations of the National Comprehensive Cancer Network, the Commission on Cancer, and the proposed complete resection definition of the International Association for the Study of Lung Cancer across the three cohorts. RESULTS: Of 3734 resections, 39% were preintervention, 40% kit, and 21% HA cases. Cohort proportions were the following: pNX, 11% (baseline) versus 0% (kit) versus 9% (HA); nonexamination of mediastinal lymph nodes, 27% versus 1% versus 22%; Commission on Cancer benchmark attainment, 14% versus 77% versus 30%; International Association for the Study of Lung Cancer-defined complete resection, 11% versus 58% versus 24%; National Comprehensive Cancer Network attainment, 23% versus 79% versus 35% (p < 0.001 for all, except pNX rate baseline versus HA). Survival rate was significantly higher for both interventions compared with baseline (p < 0.0001). CONCLUSIONS: Resections with HA or the kit significantly improved surgical quality and outcomes, but the kit was more effective. We propose to conduct a prospective, institutional cluster-randomized clinical trial comparing both interventions.
Keywords:
American College of Surgeons Operative Standard 5.8; Heightened awareness; Lymph node specimen collection kit; Quality of care; Surgical resection
Authors: Raymond U Osarogiagbon; Meredith A Ray; Nicholas R Faris; Matthew P Smeltzer; Carrie Fehnel; Cheryl Houston-Harris; Raymond S Signore; Laura M McHugh; Paul Levy; Lynn Wiggins; Vishal Sachdev; Edward T Robbins Journal: Ann Thorac Surg Date: 2017-03-31 Impact factor: 4.330
Authors: Ad F Verhagen; Micha C J Schoenmakers; Wout Barendregt; Hans Smit; Wim-Jan van Boven; Monica Looijen; Erik H F M van der Heijden; Henry A van Swieten Journal: Eur J Cardiothorac Surg Date: 2012-01-18 Impact factor: 4.191
Authors: John G Edwards; Kari Chansky; Paul Van Schil; Andrew G Nicholson; Souheil Boubia; Elisabeth Brambilla; Jessica Donington; Françoise Galateau-Sallé; Hans Hoffmann; Maurizio Infante; Mirella Marino; Edith M Marom; Jun Nakajima; Marcin Ostrowski; William D Travis; Ming-Sound Tsao; Yasushi Yatabe; Dorothy J Giroux; Lynn Shemanski; John Crowley; Marc Krasnik; Hisao Asamura; Ramón Rami-Porta Journal: J Thorac Oncol Date: 2019-11-13 Impact factor: 15.609
Authors: Timothy Winton; Robert Livingston; David Johnson; James Rigas; Michael Johnston; Charles Butts; Yvon Cormier; Glenwood Goss; Richard Inculet; Eric Vallieres; Willard Fry; Drew Bethune; Joseph Ayoub; Keyue Ding; Lesley Seymour; Barbara Graham; Ming-Sound Tsao; David Gandara; Kenneth Kesler; Todd Demmy; Frances Shepherd Journal: N Engl J Med Date: 2005-06-23 Impact factor: 91.245
Authors: Kenneth L Kehl; David Zahrieh; Ping Yang; Shauna L Hillman; Angelina D Tan; Jacob M Sands; Geoffrey R Oxnard; Erin A Gillaspie; Dennis Wigle; Shakun Malik; Thomas E Stinchcombe; Suresh S Ramalingam; Karen Kelly; Ramaswamy Govindan; Sumithra J Mandrekar; Raymond U Osarogiagbon; David Kozono Journal: JAMA Oncol Date: 2022-05-01 Impact factor: 33.006
Authors: Matthew P Smeltzer; Nicholas R Faris; Carrie Fehnel; Olawale Akinbobola; Andrea Saulsberry; Meghan Meadows-Taylor; Alicia Pacheco; Meredith Ray; Raymond U Osarogiagbon Journal: JTO Clin Res Rep Date: 2021-03-09